Weezion, a labelized Deeptech company, was created in 2020 to develop and promote a rapid and economic solution for In-vitro Diagnosis (IVD) of bacteremia or fungemia responsible for sepsis including the identification of microorganisms and the prediction of antibiotic sensibility and resistance.
Weezion is the result of 5 years of research by several academic and scientific teams from the Institute of Infectious Agents at the Croix Rousse Hospital in Lyon, the Institute of Analytical Sciences and the International Infectious Disease Research Centre of the Claude Bernard Lyon 1 University.
The main stages of the medical research that led to the creation of Weezion were accomplished within the framework of IdBIORIV, winner of the “Hospital-University Research in Health (RHU)” project of the Investments for the Future Program, led by ANR, the French Research Agency.
Medical Scientific Industrial Strategic expertise
INSA Engineer & EM LYON MBA
Hervé has held several managerial positions in R&D, Manufacturing, Marketing and Sales within a multinational company. During this time he managed multiple industrial sites on all continents, created the group’s centralized R&D centre, launched several innovative products as Director of Operations, authored 2 patents, and established numerous industrial and commerical partnerships internationally.
Since 2013, Hervé has advised and supported business leaders in the development and implementation of their internal and external growth and innovation strategies.
Hervé advised Jérôme Lemoine during his first entrepreneurial experience in 2014 and for the creation of Weezion before joining the company as CEO.
University Professor at Claude Bernard Lyon 1 University, Head of the ANABIO-MS team at the Institute of Analytical Sciences Analytiques UMR CNRS 5280. Inventor of the patented Scout-MRM process.
Jérome’s research focuses on the development of new instruments and methodologies for the structural and quantitive analysis of biomolecules. He has been the coordinator or the main partner of several ANR projects and coordinator of 9 industrial research partnerships with bioMérieux, Sanofi, Sciex and Sanofi Pasteur over the past 10 years. Alongside his team, he developed and transferred targeted mass spectrometry methods to industrial sites.
Expert in the development and validation of methods for detecting and assaying proteins and bio-therapeutics by mass spectrometry, he is the inventor of the Scout-MRM patent for which Weezion has obtained a license in the exclusive field of infection diagnosis.
University Professor – Hospital Practitioner (PU-PH), Head of the Bacteriology Department at the Institute of Infectious Agents at the Croix-Rousse Hospital, Director of the National Reference Centre for Staphylococci.
François led the creation of the Institue of Infectious Agents with consisted of regrouping 7 microbiology departments from the public hospitals in Lyon, France into one single entity at the Croix Rousse Hospital. In his role as Deputy Director, he also contributed to the foundation of the International Center for Research in Infectious Disease.
François also has experience working with industrial partners, particularly with bioMérieux, in collaborative projects focused on laboratory automation and mass spectrometry.
A targeted mass spectrometry method that determines a large panel of peptide reporters from proteins associated with pathogen identity, and which together detects and quantifies proteins associated with antibiotic resistance
2015 - 2019
Development of the Mass Spectometry Method (ESI Scout MRM)
Creation of the peptide reporter database
Winner of the Investments of the Future Program
RHU IdBIORIV is the winner of the French Government’s “Investment for the Future” Program, which finances innovative projects in priority sectors
Creation of Weezion
Young University Start-up, labelized Deeptech
Weezion integrates IdBIORIV, RHU.
Exclusive contract for all IP from the project
Filling of 3 new patents
2022 - 2024
Test Kits Design
Interpretation & Acquisition Software
2023 - 2024
At the Croix-Rousse Hospital, Lyon, France
2024 - 2025
2024 - 2025
2025 - 2026